ID   D425 Med
AC   CVCL_1275
SY   D-425 Med; D-425 Med-C; D-425MED; D425_Med; D425MED; D425Med; Med 425; D-425; D425; H425
DR   BioGRID_ORCS_Cell_line; 1665
DR   cancercelllines; CVCL_1275
DR   Cell_Model_Passport; SIDM01501
DR   Cosmic; 973264
DR   Cosmic; 2362651
DR   Cosmic; 2772985
DR   DepMap; ACH-001053
DR   GEO; GSM482334
DR   GEO; GSM919359
DR   Lonza; 1683
DR   Millipore; SCC290
DR   Progenetix; CVCL_1275
DR   Wikidata; Q54817229
RX   PubMed=1822845;
RX   PubMed=1904513;
RX   PubMed=2180567;
RX   PubMed=11916498;
RX   PubMed=20847082;
RX   PubMed=21177782;
RX   PubMed=21667264;
RX   PubMed=22343310;
RX   PubMed=24297863;
RX   PubMed=24300787;
RX   PubMed=27498314;
RX   PubMed=27812533;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Doubling time: 2.58 days (PubMed=1904513).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Cys (c.820_821GT>TG); Zygosity=Unspecified (PubMed=22343310; DepMap).
CC   Omics: Deep exome analysis.
CC   Derived from site: In situ; Brain, posterior fossa; UBERON=UBERON_0008788.
ST   Source(s): Millipore
ST   Amelogenin: X
ST   CSF1PO: 9,12
ST   D13S317: 11
ST   D16S539: 11,12
ST   D18S51: 15,17,18
ST   D21S11: 29,33.2
ST   D3S1358: 14,17
ST   D5S818: 12,13
ST   D7S820: 11,12
ST   D8S1179: 11,15
ST   FGA: 20,24
ST   Penta D: 9,10
ST   Penta E: 14,15
ST   TH01: 6,9.3
ST   TPOX: 8
ST   vWA: 16,17
DI   NCIt; C129445; Medulloblastoma, non-WNT/non-SHH, group 3
DI   ORDO; Orphanet_616; Medulloblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_1161 ! D458 Med
SX   Male
AG   6Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 24
//
RX   PubMed=1822845;
RA   Wikstrand C.J., Friedman H.S., Bigner D.D.;
RT   "Medulloblastoma cell-substrate interaction in vitro.";
RL   Invasion Metastasis 11:310-324(1991).
//
RX   PubMed=1904513;
RA   He X.-M., Wikstrand C.J., Friedman H.S., Bigner S.H., Pleasure S.,
RA   Trojanowski J.Q., Bigner D.D.;
RT   "Differentiation characteristics of newly established medulloblastoma
RT   cell lines (D384 Med, D425 Med, and D458 Med) and their transplantable
RT   xenografts.";
RL   Lab. Invest. 64:833-843(1991).
//
RX   PubMed=2180567;
RA   Bigner S.H., Friedman H.S., Vogelstein B., Oakes W.J., Bigner D.D.;
RT   "Amplification of the c-myc gene in human medulloblastoma cell lines
RT   and xenografts.";
RL   Cancer Res. 50:2347-2350(1990).
//
RX   PubMed=11916498; DOI=10.1093/neuonc/4.2.75;
RA   Aldosari N., Wiltshire R.N., Dutra A., Schrock E., McLendon R.E.,
RA   Friedman H.S., Bigner D.D., Bigner S.H.;
RT   "Comprehensive molecular cytogenetic investigation of chromosomal
RT   abnormalities in human medulloblastoma cell lines and xenograft.";
RL   Neuro-oncol. 4:75-85(2002).
//
RX   PubMed=20847082; DOI=10.1093/neuonc/noq091;
RA   Teider N., Scott D.K., Neiss A., Weeraratne S.D., Amani V.M., Wang Y.-F.,
RA   Marquez V.E., Cho Y.-J., Pomeroy S.L.;
RT   "Neuralized1 causes apoptosis and downregulates Notch target genes in
RT   medulloblastoma.";
RL   Neuro-oncol. 12:1244-1256(2010).
//
RX   PubMed=21177782; DOI=10.1093/neuonc/noq179;
RA   Weeraratne S.D., Amani V.M., Neiss A., Teider N., Scott D.K.,
RA   Pomeroy S.L., Cho Y.-J.;
RT   "miR-34a confers chemosensitivity through modulation of MAGE-A and p53
RT   in medulloblastoma.";
RL   Neuro-oncol. 13:165-175(2011).
//
RX   PubMed=21667264; DOI=10.1007/s00726-011-0953-8;
RA   Azizi A.A., Li L., Strobel T., Chen W.-Q., Slavc I., Lubec G.;
RT   "Identification of c-myc-dependent proteins in the medulloblastoma
RT   cell line D425Med.";
RL   Amino Acids 42:2149-2163(2012).
//
RX   PubMed=22343310; DOI=10.1016/j.neulet.2012.02.022;
RA   Ghassemifar S., Mendrysa S.M.;
RT   "MDM2 antagonism by nutlin-3 induces death in human medulloblastoma
RT   cells.";
RL   Neurosci. Lett. 513:106-110(2012).
//
RX   PubMed=24297863; DOI=10.1158/1078-0432.CCR-13-2281;
RA   Bandopadhayay P., Bergthold G., Nguyen B., Schubert S., Gholamin S.,
RA   Tang Y.-J., Bolin S., Schumacher S.E., Zeid R., Masoud S., Yu F.-R.,
RA   Vue N., Gibson W.J., Paolella B.R., Mitra S.S., Cheshier S.H., Qi J.,
RA   Liu K.-W., Wechsler-Reya R.J., Weiss W.A., Swartling F.J., Kieran M.W.,
RA   Bradner J.E., Beroukhim R., Cho Y.-J.;
RT   "BET bromodomain inhibition of MYC-amplified medulloblastoma.";
RL   Clin. Cancer Res. 20:912-925(2014).
//
RX   PubMed=24300787; DOI=10.1158/1078-0432.CCR-13-2053;
RA   Erdreich-Epstein A., Robison N., Ren X.-H., Zhou H., Xu J.-Y.,
RA   Davidson T.B., Schur M., Gilles F.H., Ji L.-Y., Malvar J.,
RA   Shackleford G.M., Margol A.S., Krieger M.D., Judkins A.R., Jones D.T.W.,
RA   Pfister S.M., Kool M., Sposto R., Asgharzadeh S.;
RT   "PID1 (NYGGF4), a new growth-inhibitory gene in embryonal brain tumors
RT   and gliomas.";
RL   Clin. Cancer Res. 20:827-836(2014).
//
RX   PubMed=27498314; DOI=10.1016/j.jbiotec.2016.07.028;
RA   Ivanov D.P., Coyle B., Walker D.A., Grabowska A.M.;
RT   "In vitro models of medulloblastoma: choosing the right tool for the
RT   job.";
RL   J. Biotechnol. 236:10-25(2016).
//
RX   PubMed=27812533; DOI=10.1016/j.dib.2016.10.004;
RA   Ivanov D.P., Walker D.A., Coyle B., Grabowska A.M.;
RT   "Data on the number and frequency of scientific literature citations
RT   for established medulloblastoma cell lines.";
RL   Data Brief 9:696-698(2016).
//